Viekira Pak Lawsuit | 2025 Latest Updates

Side effects of Viekira Pak may include severe liver disease resulting in transplantation or death, according to a warning from the FDA.
Award Logos
C.L. Mike Schmidt Published by C.L. Mike Schmidt
Free Confidential Viekira Pak Lawsuit Review
If you or a loved one experienced liver failure, required a liver transplant, or died after taking Viekira Pak, you may be entitled to pursue compensation.

At Schmidt&Clark, we are dedicated to helping individuals who have suffered due to contaminated food products. Our experienced legal team is here to guide you through the process and fight for the compensation you deserve.

Contact Schmidt&Clark today for a free, no-obligation consultation.

Start My Free Case Review

Viekira Pak Lawsuit Overview

Viekira Pak lawsuits primarily involve allegations of severe liver injuries, including liver failure and death, in patients who took the hepatitis C medication. Manufactured by AbbVie, the drug received an FDA warning on October 22, 2015, about serious liver injury risks, particularly in patients with underlying advanced liver disease. At least 26 adverse events have been reported through the FDA’s FAERS monitoring system, with some cases resulting in liver transplantation or death, typically occurring within one to four weeks of starting treatment.

Latest Viekira Pak Lawsuit Updates

December 1, 2016 – A study published in PubMed found that Technivie could pose a hepatotoxic risk, particularly for patients with preexisting liver issues, underscoring the importance of proper screening and risk communication by drug makers [1].

August 24, 2016 – According to a 2015 FDA safety communication, Technivie and similar Hepatitis C treatments have been associated with severe liver injury in some patients, including cases of liver failure and death [2].

FDA Reports and Statistics

According to the FDA Adverse Event Reporting System (FAERS) database, at least 26 cases of hepatic decompensation and liver failure have been reported in patients taking Viekira Pak, with these adverse events typically occurring within one to four weeks of starting treatment.

The FDA’s analysis of these reports led to an October 22, 2015, safety communication and subsequent label changes for Viekira Pak. The agency specifically noted that, of the reported cases, at least 10 resulted in liver transplantation or death, highlighting the severity of the potential side effects.

Viekira Pak Injuries & Side Effects

Viekira Pak has been associated with a range of side effects, from mild to severe, with liver-related complications being the most serious concern.

  • Liver Disease: Including hepatic decompensation and liver failure, particularly in patients with existing cirrhosis
  • Allergic Reactions: Including severe rash and other hypersensitivity responses
  • Blood Disorders: Including anemia and thinning blood
  • General Side Effects: Including fatigue, weakness, nausea, dizziness, itching, and difficulty sleeping

Do You Qualify for a Viekira Pak Lawsuit?

You may qualify for a Viekira Pak lawsuit if:

  • You were prescribed and took Viekira Pak for hepatitis C treatment
  • You experienced serious liver-related side effects such as liver disease, liver failure, or hepatic decompensation
  • You required medical treatment, hospitalization, or a liver transplant due to complications after taking Viekira Pak
  • You can provide medical documentation linking your injuries to Viekira Pak use

Evidence Required for a Viekira Pak Lawsuit

  • Medical records confirming your Viekira Pak prescription
  • Documentation of liver injuries or other serious side effects following Viekira Pak use
  • Medical tests and physician notes establishing a connection between Viekira Pak and your injuries
  • Proof of medical expenses, lost wages, and other damages resulting from your injuries

Damages You Can Recover

  • Medical expenses, including costs for hospitalization, liver transplant, and ongoing care
  • Lost wages and diminished earning capacity
  • Pain and suffering associated with your injuries
  • Punitive damages against AbbVie for failing to adequately warn about risks
  • In cases of death, family members may recover wrongful death damages

Statute of Limitations for Viekira Pak Lawsuits

The statute of limitations for filing a Viekira Pak lawsuit varies by state but typically ranges from one to three years from the date you discovered or should have discovered your injury was related to the medication. It’s crucial to consult with an attorney as soon as possible to ensure your legal rights are protected before the filing deadline expires.

Related Article: Technivie Lawsuit (Risk of Liver Damage)

FAQs

1. What is Viekira Pak?

Viekira Pak is an antiviral medication containing dasabuvir, ombitasvir, paritaprevir, and ritonavir. These drugs prevent hepatitis C virus (HCV) from multiplying in the body. It’s used to treat genotype 1 chronic hepatitis C in adults, including people with compensated cirrhosis.

2. What are the symptoms of liver disease caused by Viekira Pak?

Symptoms of liver disease may include fatigue, weakness, loss of appetite, nausea, vomiting, yellow eyes or skin (jaundice), and light-colored stools. If you experience any of these symptoms while taking Viekira Pak, contact your doctor immediately.

3. What did the FDA recommend for patients taking Viekira Pak?

The FDA recommends that patients who develop symptoms of liver disease contact their doctor immediately. Patients should not stop taking Viekira Pak without consulting their physician, as doing so could result in drug resistance to other hepatitis C medications.

4. Is there a class action lawsuit for Viekira Pak?

No class action lawsuit has yet been filed in the Viekira Pak litigation. However, if multiple lawsuits are filed alleging similar injuries, these complaints may be consolidated into a multidistrict litigation (MDL) for pretrial handling.

5. Have there been any settlements in Viekira Pak lawsuits?

The first Viekira Pak lawsuits have only recently been filed, and the proceedings are still in their early stages. It will likely be several years before AbbVie considers settling some or all of the cases.

6. What are the long-term effects of liver damage caused by Viekira Pak?

Long-term effects of liver damage caused by Viekira Pak can include chronic liver disease, cirrhosis, liver failure, and the need for a liver transplant. These conditions require ongoing medical treatment and can significantly impact quality of life.

7. Are there any alternatives to Viekira Pak for treating hepatitis C?

Yes, there are alternative medications for treating hepatitis C, including Harvoni, Sovaldi, and Zepatier. Patients should consult their healthcare provider to determine the best treatment option based on their medical condition and history.

Time is limited to pursue legal action for Viekira Pak injuries. Most states only allow one to three years from the date of injury to file a pharmaceutical liability lawsuit. Don’t wait until it’s too late to seek the compensation you deserve.

Schmidt&Clark firm offers:

  • Free, confidential consultations to evaluate your case
  • No upfront costs or fees for our legal services
  • Payment only if we win your case through settlement or verdict

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Viekira Pak lawsuits. We are handling individual litigation nationwide and currently accepting new liver disease cases in all 50 states.

Free Case Evaluation: Again, if you had liver failure or required a liver transplant, or someone you know died after taking Viekira Pak, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

References:

[1] https://pubmed.ncbi.nlm.nih.gov/28044114/  

[2] https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-serious-liver-injury-risk-hepatitis-c-treatments-viekira-pak 

Get a Free Case Review

You may be entitled to financial compensation.
Secure Submission